EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 30, 2015

Primary Completion Date

April 20, 2018

Study Completion Date

May 16, 2018

Conditions
Cystic Fibrosis
Interventions
DRUG

CTX-4430

DRUG

Placebo

Trial Locations (75)

10032

Columbia University Medical Center, New York

10117

Charite' University, Berlin

12208

Albany Medical College, Albany

13210

SUNY Upstate Medical University, Syracuse

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

17033

Hershey Medical Center, Hershey

19104

Drexel University, Philadelphia

The Children's Hospital of Philadelphia, Philadelphia

23298

Virginia Commonwealth University, Richmond

27157

Wake Forest Hospital, Winston-Salem

30322

Emory University, Atlanta

32610

University of Florida, Gainesville

32803

Central Florida Pulmonary Group, Orlando

35233

University of Alabama, Birmingham

37920

Universiy of Tennessee Medical Center UHS, Knoxville

39216

University of Mississippi Medical Center, Jackson

45267

UC Cincinnati Children's Hospital, Cincinnati

48201

Harper University Hospital, Detroit

49286

University of Michigan, Ann Arbor

49546

Spectrum Health Butterworth Campus, Grand Rapids

53226

Medical College of Wisconsin, Milwaukee

57104

Sanford Clinical Research, Sioux Falls

60637

University of Chicago, Chicago

61637

St. Francis Medical Center, Peoria

66160

University of Kansas Medical Center, Kansas City

73104

University of Oklahoma Health Sciences Center, Oklahoma City

76104

Cook Children's Hospital, Fort Worth

78723

Dell Children's Medical Center, Austin

80206

National Jewish Health, Denver

85724

Banner University of Arizona Medical Center, Tucson

87131

University of New Mexico, Albuquerque

90027

Childrens Hospital Los Angeles, Los Angeles

94304

Pediatric Pulmonary and Cystic Fibrosis Clinic, Stanford University, Palo Alto

95817

University of California Davis Medical Center, Sacramento

97239

Oregon Health & Sciences University, Portland

99508

Providence Health and Services, Anchorage

06520

Yale University, New Haven

04106

Maine Medical Center, Portland

02114

Massachusetts General Hospital, Boston

02115

Boston Children's Hospital, Boston

Unknown

Hôpital Erasme, Brussels

UZ Leuven, Leuven

Centre hospitalier de Dunkerque, Dunkirk

Hôpital Albert Michallon, Grenoble

Hôpital Cochin, Paris

CH Lyon Sud, Pierre-Bénite

Krankenhaus Donaustauf, Donaustauf

"Carl-Gustav-Klinikum Dresden, Mukoviszidose Centrum Christiane Herzog", Dresden

Ruhrlandklinik Essen, Essen

Institut für klinische Forschung Pneumologie, Frankfurt

Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt

Medizinische Hochschule Hannover, Hanover

Lungenärztliche Praxis München-Pasing, München-Pasing

Klinikum Stuttgart CF Ambulanz, Stuttgart

Ospedali Riuniti di Ancona, Ancona

Azienda Ospedaliero Universitaria, Catania

Azienda Ospedaliera A Meyer, Florence

IRCCS Ospedale Pediatrico Bambino, Rome

Ospedale Civile Maggiore, Verona

Belfast City Hospital, Belfast

Liverpool Heart and Chest Hospital, Liverpool

Royal Brompton Hospital, London

University Hospital of South Manchester, Manchester

Royal Victoria Infirmary, Newcastle upon Tyne

University Hospital Southampton, Southampton

Royal Stoke University Hospital, Stoke-on-Trent

T2N 4N1

University of Calgary, Calgary

K1H 8L6

Ottawa Hospital, Ottawa

m5B 1W8

St. Michael's Hospital, Toronto

Cedex 5

Hopital Arnaud de Villeneuve, Montpellier

07740

Universitätsklinikum Jena CF Centre, Jena

BS2 8HW

Bristol Royal Infirmary, Bristol

CF64 2XX

Llandough Hospital, Cardiff

LS97TF

St James's University Hospital, Leeds

SE5 9RS

King's College Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celtaxsys, Inc.

OTHER

NCT02443688 - EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients | Biotech Hunter | Biotech Hunter